Additionally, SMGT-GLP-1 offers cardiovascular protection by reducing the risk of heart disease, improving lipid profiles, and providing anti-inflammatory effects, further protecting vascular health
The low number of clinical studies and the heterogeneous study designs significantly constrain our ability to draw conclusions regarding the effects of dietary interventions to modulate the detrimental effects of ES in human subjects and stresses the need to perform randomized clinical trials in humans
However, by improving insulin resistance and promoting weight loss, it may indirectly support ovarian function and overall fertility
EMA statement on ongoing review of GLP-1 receptor agonists
Compounded 2.5mg/ml Injectable Semaglutide Suggested Dose: Inject 0.1ml once weekly subcutaneously weeks 1-4, Increase dose to 0.2ml once weekly on weeks 5-8, increase dose to 0.4ml once weekly on weeks 9-12, increase dose to 0.68ml once weekly on weeks 13-16, if a dosage increase is still needed, increase to 0.96ml once weekly for maintenance